Potential new biomarkers for advanced ccRCC treatment response identified

Potential new biomarkers for advanced ccRCC treatment response identified

Biomarkers of treatment response in patients with MMR-proficient CRCПодробнее

Biomarkers of treatment response in patients with MMR-proficient CRC

#KCRS20: Emerging Biomarkers for Kidney CancerПодробнее

#KCRS20: Emerging Biomarkers for Kidney Cancer

LITESPARK-005: Belzutifan versus everolimus in ccRCCПодробнее

LITESPARK-005: Belzutifan versus everolimus in ccRCC

New Biomarkers for Diagnosis and PrognosisПодробнее

New Biomarkers for Diagnosis and Prognosis

Assessing immune biomarkers of response to anthracyclines in breast cancerПодробнее

Assessing immune biomarkers of response to anthracyclines in breast cancer

The role of molecular biomarkers in determining patient response to bladder cancer treatmentПодробнее

The role of molecular biomarkers in determining patient response to bladder cancer treatment

Biomarkers in Kidney Cancer: Session One - KCRS23 | KidneyCANПодробнее

Biomarkers in Kidney Cancer: Session One - KCRS23 | KidneyCAN

Predicting treatment responses with CTCs in ccRCCПодробнее

Predicting treatment responses with CTCs in ccRCC

UNITE: biomarkers of response to enfortumab vedotin in patients with advanced urothelial carcinomaПодробнее

UNITE: biomarkers of response to enfortumab vedotin in patients with advanced urothelial carcinoma

Guadecitabine and Durvalumab in Advanced Clear Cell RCCПодробнее

Guadecitabine and Durvalumab in Advanced Clear Cell RCC

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

Progress in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid TumorsПодробнее

Progress in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors

2024 Kidney Cancer Patient and Caregiver Education Symposium (July 27, 2024)Подробнее

2024 Kidney Cancer Patient and Caregiver Education Symposium (July 27, 2024)

Biomarkers to help predict response to CDK4/6 inhibitorsПодробнее

Biomarkers to help predict response to CDK4/6 inhibitors

Fine-Tuning Biomarker Testing to Identify and Target RET Fusions in NSCLCПодробнее

Fine-Tuning Biomarker Testing to Identify and Target RET Fusions in NSCLC

Sitravatinib and nivolumab in ccRCC following progression on antiangiogenic therapyПодробнее

Sitravatinib and nivolumab in ccRCC following progression on antiangiogenic therapy

New biomarkers for response to immunotherapyПодробнее

New biomarkers for response to immunotherapy

Neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccRCCПодробнее

Neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccRCC

Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic AlterationsПодробнее

Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations